FDA approves first gene therapy for adults with blood cancer


The Food and Drug Administration on Wednesday approved a one-time treatment for lymphoma in adults, only the second time a gene therapy for blood cancer has been given the okay in the United States.
This is the first gene therapy approved for adults, and it involves removing a patient's T cells, reprogramming them to find and kill cancer cells, then putting the cells back into the patient, The Associated Press reports. The treatment uses the same technology as a gene therapy recently approved in the U.S. for childhood leukemia, and will cost $373,000 per patient, its manufacturer said.
Subscribe to The Week
Escape your echo chamber. Get the facts behind the news, plus analysis from multiple perspectives.

Sign up for The Week's Free Newsletters
From our morning news briefing to a weekly Good News Newsletter, get the best of The Week delivered directly to your inbox.
From our morning news briefing to a weekly Good News Newsletter, get the best of The Week delivered directly to your inbox.

Continue reading for free
We hope you're enjoying The Week's refreshingly open-minded journalism.
Subscribed to The Week? Register your account with the same email as your subscription.